Phase II Study to Evaluate the Efficacy and Safety of HAIC Combined With Toripalimab and Donafenib in Patients With Advanced Biliary Tract Cancer

Lu Wang, MD, PhD1 个研究点分布在 1 个国家目标入组 70 人开始时间: 2022年3月1日最近更新: 2022年10月18日

适应症

干预措施

试验速览

阶段: 2 期
状态: Enrolling By Invitation
发起方
入组人数: 70
试验地点: 1
主要终点: Objective response rate (ORR)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This is a single center, single arm, phase II, prospective study to evaluate the efficacy and safety of Hepatic Arterial Infusion Chemotherapy (HAIC) combined with PD-1 inhibitor immunotherapy Toripalimab and Tyrosine Kinase Inhibitor Donafenib in patients with advanced biliary tract cancer.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 80 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•18 to 80 years of age, of any sex;
•Histologically/Cytologically confirmed diagnosis of unresectable advanced adenocarcinoma of the gallbladder, intrahepatic bile duct and extrahepatic bile duct.
•At least one measurable lesion umder CT/MRI as defined by RECIST1.1 criteria
•Patients must have adequate organ and marrow function as defined below:
•Blood test:
•Hemoglobin (HB) ≥90 g/L Absolute neutrophil count (ANC) ≥1.5×10^9/L； Platelet (PLT) ≥80×10^9/L；
•Biochemical test:
•total bilirubin≤2×ULN (institutional upper limit of norm) AST(SGOT)/ALT(SGPT)≤2.5 ×ULN creatinine clearance≥ 50 ml/min as calculated by the Cockroft-Gault formula
•Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-1;
•Indocyanine Green Retention Rates at 15 min (ICGR15<22%;
•Life expectancy of > 3 months;
•Exclusion Criteria
•Patients with other malignant tumors should be excluded
•Female patients who are pregnant or breast-feeding. Female patients who are pregnant during the study should also exit.
•Patient has enter any other clinical trails within 4 weeks prior to study entry.
•Patient known with a severe and/or uncontrolled medical disease.
•Chronic non-healing wound/bone fracture
•History of organ transplant
•Patients with abnormal coagulation function (PT>16s, APTT>43s, TT>21s, Fbg<2g/L), those have bleeding tendency (14 days prior to randomization must meet: INR is within the normal range without any use of anticoagulants); patients treated with anticoagulants or vitamin K antagonists such as warfarin, heparin or analogous therapy; use for preventive purposes is permitted provided that the international normalized ratio of prothrombin time (INR) ≤ 1.5, take low-dose warfarin (1 mg PO, QD) or low-dose aspirin (do not exceed 100 mg per day);
•Previous history of aterial/venous thrombosis such as cerebrovascular accidents, pulmonary embolism or deep venous thrombosis within one year prior to patients recruitment.
•Hitstory of psychiatric drug abuse and hasn't come clean, or with psychiatric illness/social situations that would limit compliance with study requirements
•History of immunodeficiency, or other acquired/congenital immunodeficiency diseases
•Concomitant diseases that severely endanger the safety of the subject or affect the study completion according to the judgment of the investigator
•Willingness to sign a written informed consent document, with good compliance.

排除标准

未提供